Clinical trial NCT01474395: N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
Official title: NMDA and Cognitive Remediation in Schizophrenia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Schizophrenia
Schizoaffective Disorder
Keywords: schizophrenia
cognitive remediation
NMDA
Lead sponsor: Nathan Kline Institute for Psychiatric Research
Sponsor class: OTHER
Collaborators: name: Columbia University
First posted: 2011-11-18
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Persistent neurocognitive deficits are a major cause of severe disability and impaired long-term psychosocial outcome in schizophrenia (SZ). In particular, within the auditory system, early deficits such as the behavioral and neurophysiological ability to match tones that vary in pitch correlate with impairments in auditory emotion recognition (affective prosody) and general functioning, suggesting that interventions aimed at remediating sensory-level dysfunction may lead to significant improvement in higher order cognitive/emotion processes. Efforts to ameliorate cognitive deficits in schizophrenia utilize either pharmacological agents or behavioral treatments such as cognitive remediation, which generally focus on higher order processes, and not on the early sensory processing which may be key to functioning.

Numerous pharmacological agents have been proposed, but accumulating evidence suggests that dysfunction of the N-methyl-D-aspartic acid (NMDA) receptor may be one of the root causes of schizophrenia, including sensory and cognitive impairments, suggesting that an NMDA based treatment may be efficacious in reversing these deficits. D-Cycloserine, a synthetic partial NMDA agonist has been used in anxiety disorders to augment learning in cognitive remediation. Because of a tendency to act as an NMDA antagonist at higher doses D-cycloserine is not effective in schizophrenia. In contrast, D-serine (DSR), is a full agonist, and is therefore more ideal for enhancing NMDA function and cognitive remediation. While previous use of DSR was limited by safety concerns in rodents,the investigators have shown that it can safely be used at doses of 60 mg/kg and, moreover, demonstrates converging improvement in symptomatic, cognitive and sensory-based measures in schizophrenia. Evidence also suggests that NMDA receptor dysfunction in schizophrenia may be relative, rather than absolute, suggesting that the enhanced practice of a cognitive remediation paradigm might be able to overcome reduced plasticity and treat cognitive dysfunction.

This project will be the first to combine the NMDA based and sensory-based cognitive remediation (SBR) approaches, and will utilize not only DSR, but also a tone matching SBR paradigm has been shown to enhance learning in healthy controls, as well as a paradigm designed to augment visual motion detection. This study will pilot these interventions in a double-blind, placebo-controlled, randomized crossover design that will use neurophysiology together with cognitive tests to explore the effects on brain activity and cognitive function in 16 patients with schizophrenia or schizoaffective disorder. The investigators hypothesize that DSR+SBR will lead to improvement. Subjects will have an initial visit to establish baseline performance on cognitive tasks before returning for 3 visits when they will receive blinded study medication \[60 mg/kg of DSR (2 days) or placebo (1 day)\] in a randomized order. The procedures on the treatment days will include the SBR paradigm and pre/post neurophysiological measurements. Primary outcomes are improvements in neurophysiologic and behavioral sensory processing. The main goal is to establish the preliminary efficacy to use in a follow-up multi-dose study utilizing a multiple session SBR R01 application.


Eligibility criteria: Inclusion Criteria:

* 18 to 64 years old, IQ≥85 and estimated Glomerular Filtration Rate (GFR) \< or =60. All oral and depot antipsychotics (with the exception of clozapine) are allowable.
* Patients must be on their antipsychotic medication for 1 month and stable on dose of antipsychotic and adjunctive medications for 2 weeks prior to study entry.

Exclusion Criteria:

* Include a history of neurological visual or hearing impairment, active suicidal ideation on the Calgary Depression Scale (CDS), current alcohol or drug abuse (\<1 month) or substance dependence (\<4 months).
* All women of child-bearing potential must have a negative serum pregnancy test at the baseline visit.
* We require an IQ of greater or equal to 85 to ensure that subjects will have a capacity to learn.
* In our cross-sectional studies, we have observed an IQ greater than 85 in over 90% of candidates, suggesting that this is not an overly restrictive criterion.

Primary outcomes:
measure: Tone Matching threshold
timeFrame: 3 weeks
measure: Mismatch Negativity (MMN)
timeFrame: 3 weeks
Secondary outcomes:
measure: Tone Matching
timeFrame: 3 weeks
measure: Auditory Emotion Recognition Task
timeFrame: 3 weeks
measure: Positive and Negative Symptom Scale (PANSS
timeFrame: 3 weeks
measure: Medical Symptom Inventory (aka Side Effect Checklist)
timeFrame: 3 weeks
measure: MATRICS consensus cognitive battery,
timeFrame: 3 weeks
measure: Contrast sensitivity
timeFrame: 3 weeks
measure: The Perceptual Organization Index (POI):
timeFrame: Baseline-final
measure: Emotion in motion
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Orangeburg
country: United States
facility: Nathan Kline Insitute for Psychiatric Research
state: New York
Study officials:
affiliation: Columbia University/Nathan Kline Institute
name: Joshua T Kantrowitz, MD
role: PRINCIPAL_INVESTIGATOR
References: